Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications

A hydroxymethylglutaryl coenzyme and glycosidase inhibitor technology, applied in the field of medicine, can solve problems such as poor compliance of diabetic patients, low diagnosis rate, and lack of long-term treatment

Inactive Publication Date: 2013-06-05
乔文龙
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The annual direct medical cost of diabetes in my country exceeds 18 billion, accounting for 4% of the total medical cost. Although there are so many patients, the low diagnosis rate, the chronic course of the disease, the need for combination therapy, and the lack of effective long-term Oral medications for diabetes and poor patient compliance associated with injectable treatments mean there are still many unmet needs in this area

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications
  • Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications
  • Alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Preparation of Compound Acarbose Simvastatin Tablets (1000 Tablets)

[0035] Recipe: Acarbose 100g

[0036] Simvastatin 10g

[0037] Microcrystalline Cellulose 50g

[0038] Starch 50g

[0039] Sodium carboxymethyl starch 20g

[0040] Low-substituted hydroxypropyl cellulose 20g

[0041] Proper amount of povidone ethanol solution

[0042] Magnesium Stearate 1%

[0043] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 100g of acarbose and 10g of simvastatin and mix them uniformly according to the method of equal increments, add starch, microcrystalline cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose respectively according to the prescription amount, and follow the method of equal increments Mix evenly, make soft material with 5% povidone K29 / 30-95% ethanol solution, granulate with 20 mesh sieve, dry at 40°C for about 2...

Embodiment 2

[0044] Example 2 Preparation of Compound Acarbose Rosuvastatin Tablets (1000 Tablets)

[0045] Recipe: Acarbose 100g

[0046] Rosuvastatin 10g

[0047] Microcrystalline Cellulose 50g

[0048] Starch 50g

[0049] Sodium carboxymethyl starch 20g

[0050] Low-substituted hydroxypropyl cellulose 20g

[0051] Proper amount of povidone ethanol solution

[0052] Magnesium Stearate 1%

[0053] The preparation method was the same as in Example 1, and each tablet contained 100 mg of acarbose and 10 mg of rosuvastatin in the prepared compound tablet.

Embodiment 3

[0054] Example 3 Preparation of Compound Acarbose Pitavastatin Tablets (1000 Tablets)

[0055] Recipe: Acarbose 100g

[0056] Pitavastatin 2g

[0057] Microcrystalline Cellulose 50g

[0058] Starch 50g

[0059] Sodium carboxymethyl starch 20g

[0060] Low-substituted hydroxypropyl cellulose 20g

[0061] Proper amount of povidone ethanol solution

[0062] Magnesium Stearate 1%

[0063] The preparation method was the same as in Example 1, and each tablet contained 100 mg of acarbose and 2 mg of pitavastatin in the prepared compound tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an alpha-glycosidase inhibitor and hydroxymethyl glutaryl coenzyme A reductase inhibitor composition for treating diabetes and complications. The medicinal composition consists of an alpha-glycosidase inhibitor or a pharmaceutically acceptable salt thereof, a hydroxymethyl glutaryl coenzyme A reductase inhibitor or a pharmaceutically acceptable salt thereof and a medicinal carrier or an excipient, wherein the alpha-glycosidase inhibitor is acarbose, voglibose or miglitol; and the hydroxymethyl glutaryl coenzyme A reductase inhibitor is simvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin, atorvastatin, cerivastatin, mevastatin or rosuvastatin. The invention also relates to application of the medicinal composition in treatment of diabetes and prevention and treatment of diabetic complications such as diabetic nephropathy, diabetic hypertension, hyperlipidemia and dyslipidemia.

Description

technical field [0001] The invention relates to the field of medicine, in particular to an alpha-glucosidase inhibitor and a hydroxymethylglutaryl coenzyme A reductase inhibitor composition for treating diabetes and its complications. Background technique [0002] Diabetes mellitus is a common endocrine system disease with a genetic tendency. It is caused by a variety of reasons for the disorder of sugar, fat, and protein metabolism. disease. Clinically, diabetes is divided into two types: type 1 diabetes (insulin-dependent diabetes) and type 2 diabetes (non-insulin-dependent diabetes). More than 90% of patients belong to type 2 diabetes. Insulin therapy is required, and blood sugar can be controlled only by dietary regulation, but in the case of ineffective dietary regulation, supplementary drug therapy is required. [0003] At present, the incidence of diabetes is still increasing year by year. According to the data provided by the World Health Organization (WHO), the in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61P3/10A61P13/12A61P9/12A61P3/06
Inventor 乔文龙
Owner 乔文龙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com